Goldman Sachs analysts led by Steven Kron share the firm's latest conviction list, which includes 23 of the bank's top picks ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization ...

Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's ...

Fintel reports that on June 6, 2025, Goldman Sachs upgraded their outlook for MasTec (NYSE:MTZ) from Neutral to Buy. Analyst ...

Fintel reports that on June 6, 2025, Goldman Sachs downgraded their outlook for MYR Group (NasdaqGS:MYRG) from Buy to Neutral ...

Goldman Sachs initiated coverage on U.S.-listed generic pharmaceutical companies with Buy ratings on Teva Pharmaceutical Industries (NYSE:TEVA) and Amneal Pharmaceuticals (NASDAQ:AMRX), and a Neutral ...

Teva Pharmaceutical (TEVA) stock, Amneal Pharma (AMRX) stock receive Buy ratings and Viatris (VTRS) stock receives a Neutral rating at Goldman Sachs. Read more here.

Goldman Sachs has added these three stocks to its Conviction List. They all have at least 20% upside potential to the analyst ...

Elon Musk has alienated “multiple sides of the political spectrum” from Tesla, according to one prominent Wall Street analyst ...

Blackstone ’s nontraded REIT has refinanced a 59-property industrial portfolio across 13 states. It secured a $1B CMBS loan ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET.

Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025. Peter Griffith, executive vice president and chief financial ...